Ardelyx (Ardelyx) Debt-to-Equity

: 0.34 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

Ardelyx's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.4 Mil. Ardelyx's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $51.5 Mil. Ardelyx's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $166.8 Mil. Ardelyx's debt to equity for the quarter that ended in Dec. 2023 was 0.34.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Ardelyx's Debt-to-Equity or its related term are showing as below:

ARDX' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.29 Med: 0.4 Max: 0.55
Current: 0.34

During the past 12 years, the highest Debt-to-Equity Ratio of Ardelyx was 0.55. The lowest was 0.29. And the median was 0.40.

ARDX's Debt-to-Equity is ranked worse than
68% of 1072 companies
in the Biotechnology industry
Industry Median: 0.145 vs ARDX: 0.34

Ardelyx Debt-to-Equity Historical Data

The historical data trend for Ardelyx's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ardelyx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

0.29

0.42

0.55

0.37

0.34

Ardelyx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity																0.37	0.29	0.28	0.18	0.34

Competitive Comparison

For the Biotechnology subindustry, Ardelyx's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Ardelyx Debt-to-Equity Distribution

For the Biotechnology industry and Healthcare sector, Ardelyx's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Ardelyx's Debt-to-Equity falls into.

Ardelyx Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Ardelyx's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.435	+	51.547)	/	166.816
	=	0.34

Ardelyx's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(4.435	+	51.547)	/	166.816
	=	0.34

Ardelyx (NAS:ARDX) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Ardelyx Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Ardelyx's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Ardelyx (Ardelyx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ardelyx Inc (NAS:ARDX) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

ARDX:Mexico 41X:Germany 41X:Germany

Address

400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451

Website

https://www.ardelyx.com

Ardelyx Inc is a biotechnology company focused on the discovery, development, and commercialization of molecule and polymeric therapeutics to treat the gastrointestinal tract and cardiorenal diseases. The company has a proprietary drug discovery and design platform. Its lead product candidate is tenapanor, which aims to reduce the absorption of dietary sodium and phosphorus for the treatment of kidney disease, irritable bowel syndrome with constipation, and hyperphosphatemia in patients with dialysis.

Executives

David P. Rosenbaum	officer: Chief Development Officer	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
Justin A Renz	officer: Chief Financial Officer	C/O KARYOPHARM THERAPEUTICS INC., 85 WELLS AVENUE, SECOND FLOOR, NEWTON MA 02459
Elizabeth A Grammer	officer: See Remarks	78TH FOURTH AVENUE, WALTHAM MA 02451
Robert Blanks	officer: See Remarks	C/O ARDELYX, 34175 ARDENWOOD BLVD., FREMONT CA 94555
Laura A Williams	officer: Chief Medical Officer	116 HUNTINGTON AVENUE, 6TH FLOOR, BOSTON MA 02116
Robert Ora Felsch	officer: See Remarks	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD., FREMONT CA 94555
Michael Raab	director, officer: President & CEO	1119 ST PAUL STREET, BALTIMORE MD 21202
Susan Rodriguez	officer: Chief Commercial Officer	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 200, FREMONT CA 94555
David M Mott	director	1119 ST. PAUL STREET, BALTIMORE MD 21202
Forest Baskett	10 percent owner
Scott D Sandell	10 percent owner
Jeffrey W Jacobs	officer: VP, Chemistry	C/O ARDELYX, INC., 34175 ARDENWOOD BLVD, SUITE 100, FREMONT CA 94555
Muna Bhanji	director	C/O CYTOKINETICS, INCORPORATED, 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Keith Santorelli	officer: See Remarks	C/O ARDELYX, INC. 34175 ARDENWOOD BLVD, FREMONT CA 94555
Onaiza Cadoret-manier	director	2855 GAZELLE COURT, C/O IONIS PHARMACEUTICALS, INC., CARLSBAD CA 92010